Investigational drug · Phase 2
Serabelisib
Also called: FTH-001, MLN1117
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Endometrial Cancer, HR+ HER2- Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
13
Any phase or sponsor naming "Serabelisib"
First trial start
2024
Dec 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Serabelisib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometrial Cancer
- HR+ HER2- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Serabelisib" as an intervention, largest first.
- A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial CancerPivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT02725268 · 241 participants · Start Apr 1, 2016 · Primary completion Jul 2, 2019
Drug: Paclitaxel; Sapanisertib and 1 more · For: Endometrial Neoplasms
Sites: Birmingham, Alabama; Phoenix, Arizona; Greenbrae, California · 78 sites in all
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01449370 · 125 participants · Start Oct 2011 · Primary completion Jul 2015
Drug: TAK-117 · For: Metastatic Solid Tumors
Sites: Boston, Massachusetts; Detroit, Michigan; Dallas, Texas · 5 sites in all
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01899053 · 101 participants · Start Jun 28, 2013 · Primary completion Jan 31, 2017
Drug: TAK-228; TAK-117 · For: Advanced Nonhematologic Malignancies
Sites: Boston, Massachusetts; Nashville, Tennessee; San Antonio, Texas · 5 sites in all
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT02724020 · 96 participants · Start Jun 30, 2016 · Primary completion Feb 3, 2020
Drug: Everolimus; MLN0128 and 1 more · For: Clear-cell Metastatic Renal Cell Carcinoma
Sites: Los Angeles, California; Venice, Florida; West Palm Beach, Florida · 36 sites in all
- A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid TumorsStatus unknown
Petra PharmaIndustry
NCT04073680 · 60 participants (planned) · Start Sep 1, 2020 · Primary completion Jul 15, 2021
Drug: Serabelisib; Canagliflozin 300mg · For: Breast Cancer; Endometrial Cancer; Lung Cancer and 2 more
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT02625259 · 54 participants · Start Jan 8, 2016 · Primary completion May 16, 2016
Drug: TAK-117; Lansoprazole and 1 more · For: Neoplasm, Advanced or Metastatic
Faeth TherapeuticsIndustry
NCT06463028 · 40 participants (planned) · Start Dec 12, 2024 · Primary completion Sep 2028
Drug: Sapanisertib; Serabelisib and 1 more · For: Endometrial Cancer
Sites: La Jolla, California; San Francisco, California; Miami Beach, Florida · 18 sites in all
Faeth TherapeuticsIndustry
NCT05300048 · 34 participants · Start Apr 22, 2022 · Primary completion Apr 30, 2025
Drug: Serabelisib; Nab paclitaxel · For: Advanced Solid Tumor; PIK3CA Mutation; PTEN Loss of Function Mutation
Sites: Birmingham, Alabama; Anaheim, California; Los Angeles, California · 17 sites in all
Faeth TherapeuticsIndustry
NCT07558733 · 32 participants (planned) · Start Apr 22, 2026 · Primary completion May 2029
Drug: Serabelisib; Sapanisertib and 1 more · For: HR+ HER2- Breast Cancer
Sites: Los Angeles, California; Newport Beach, California; Lone Tree, Colorado · 9 sites in all
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT02551055 · 32 participants · Start Oct 15, 2015 · Primary completion Feb 17, 2017
Drug: MLN1117; TAK-659 and 3 more · For: Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
Sites: Lake Success, New York; New York, New York; Philadelphia, Pennsylvania · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Serabelisib, a Selective PI3Kα Inhibitor, for Slow-Flow Vascular Malformations in a Phase 3 Multicenter Single-Arm Study with Natural History Comparison.
Aramaki-Hattori N, Sasaki S, Murao N, et al. · J Clin Med 2026
- Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
Tyrakis PA, Kampjut D, Steele GF, et al. · Br J Cancer 2025
- A phase 2 randomized, double-blind trial of ART-001, a selective PI3Kα inhibitor, for the treatment of slow-flow vascular malformations.
Ozeki M, Tanaka A, Kuniyeda K, et al. · Orphanet J Rare Dis 2025
- Serabelisib regulates GSDMD-mediated pyroptosis, apoptosis and migration of hepatoma cells via the PI3K/Akt/E-cadherin signaling pathway.
Li M, Huang Z, Zhou Y · Adv Clin Exp Med 2024
- Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors.
Starks DC, Rojas-Espaillat L, Meissner T, et al. · Gynecol Oncol 2022
- Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
Menteş M, Karakuzulu BB, Uçar GB, et al. · Comput Biol Chem 2022
Also in development for Endometrial Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- Rina-SPRO1184, GEN1184Phase 39 trials
Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials
AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.